Web Exclusives

CHICAGO—A fentanyl pectin nasal spray provides analgesia faster than immediate-release morphine in the treatment of breakthrough cancer pain, said Andrew Davies, MD, MSc at the 46th American Society of Clinical Oncology annual meeting.
 
Breakthrough cancer pain is a transient exacerbation of pain that occurs despite relatively stable and adequately controlled background pain and has a significant impact on quality of life.
 
Read More ›

CHICAGO—A risk stratification schema can be used to identify older patients who are at risk of grade-3 to -5 toxicity from chemotherapy. The schema includes risk factors based on cancer type, patient age, upfront dose of chemotherapy, the chemotherapeutic regimen used, and history of falling, among others, said Arti Hurria, MD at the 46th American Society of Clinical Oncology annual meeting.
 
“We wanted to develop a predictive model for tolerance to therapy in older adults with cancer,” she said.
 
Read More ›

CHICAGO—Bevacizumab in combination with chemotherapy followed by maintenance bevacizumab monotherapy improves progression-free survival (PFS) over chemotherapy alone in the treatment of advanced ovarian cancers, said Robert A. Burger, MD at the 46th American Society of Clinical Oncology annual meeting.
 
Read More ›

CHICAGO—Denosumab delayed or prevented more skeletal-related adverse events than zoledronic acid in men with hormone-refractory prostate cancer and bone metastases.
 
The superior efficacy of denosumab on this end point along with its ease of administration—subcutaneous rather than intravenous—gives it an edge over zoledronic acid, said Karim Fizazi, MD, PhD, lead investigator of a study comparing the two treatments, at the 46th American Society of Clinical Oncology annual meeting.
 
Read More ›

CHICAGO—Twice-daily dosing of naproxen can reduce the incidence and severity of bone pain in cancer patients being treated with pegfilgrastim, according to data presented at the 2010 annual meeting of the American Society of Clinical Oncology.
 
Read More ›

CHICAGO—In a phase 1 study in advanced non–small-cell lung cancer (NSCLC) deemed worthy of a presentation at the American Society of Clinical Oncology’s 46th annual meeting plenary session, a multinational group of investigators reported improved survival with an oral investigational agent still unfamiliar to most oncologists.
 
Read More ›


Oncology Nurses Play a Pivotal Role in Amyloidosis Management

Although primary amyloidosis is rare, oncology nurses have a broad range of responsibilities in managing patients who develop this disorder, researchers said.

Read More ›

President Obama guaranteed Americans that after health reform became law they could keep their insurance plans and their doctors. It’s clear that this promise cannot be kept. Insurers and physicians are already reshaping their businesses as a result of Mr. Obama’s plan.

Read More ›

In the first head-to-head comparison of targeted oral tyrosine kinase inhibitors as initial treatment for early-stage chronic myeloid leukemia (CML), molecular and cytogenetic remissions were more common with nilotinib compared with imatinib, the previous standard for treating early-stage CML, said Giuseppe Saglio, MD.

Read More ›

Page 61 of 61


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: